The real fight over drug prices is not happening in Congress. It is happening in the claims switch.

by Nadia OkonkwoIndustry Provocateur, HMND

The political theater is loud, but the patient’s bill does not care about theater. It cares about whether the claims system, rebate machinery, and pricing files can actually carry Medicare Part D’s new rules without falling apart at the pharmacy counter.

The policy is not the plumbing

CMS can publish a Maximum Fair Price. That is the easy part, the ceremonial part, the part that looks decisive in a briefing room and then gets handed to systems people with a straight face. The hard part is making sure the adjudication engine recognizes the drug, the formulary logic points to the right price, and the claim resolves against the correct source of truth instead of some stale netting assumption buried in a benefit file.

That is where the real collision lives. Reform is being sold like a moral verdict. In practice, it is a data flow problem with political varnish. If rebate pass through pressure changes how PBMs account for manufacturer concessions but the downstream claims stack still prices the old way, then nothing sacred has changed. The money has merely taken a cleaner route through the same medieval pipes.

What can fail in the real world

Picture January 1, 2026. A beneficiary walks up to the counter for one of the first negotiated drugs. Nobody at that moment is debating congressional intent. They are waiting on a switch, a formulary table, a price file, and a claims response that all need to agree fast enough to keep the transaction alive.

If one layer is out of sync, the patient gets a reject, a delay, or a price that makes the whole reform look fake. CMS has already had to specify that the Maximum Fair Price must be made available at the counter, and that for certain covered entities the lower of the 340B price or the MFP applies, with the Medicare Transaction Facilitator involved in claim data exchange and payment timing. That is not a slogan. That is a multi party integration sequence with deadlines, validation rules, and enough ways to misfire to keep an entire vendor ecosystem employed.

Rebates are the old religion, and it is still in the code

PBMs built a system where list price, rebate, spread, formulary placement, and patient cost all touch each other without ever becoming the same thing. That architecture is the entire game. It is also why every reform promise runs straight into software reality.

So when people ask whether the new rules will help patients, I want a sharper question: what happens in the claims response after the adjudication engine receives the transaction, checks eligibility, applies formulary logic, and tries to settle against the negotiated price? If nobody in the room can answer that in plain language, then the reform is still mostly paperwork with a better logo.

And yes, the rebate machine is exactly why so much industry rhetoric sounds so noble while the operational stack stays ugly. You cannot legislate your way out of a pricing architecture you refuse to touch.

TrumpRx chatter is a reminder, not a solution

TrumpRx chatter is just the latest attempt to pretend a new front end can save a broken back end. It cannot. A shiny retail wrapper does not matter if the pricing source, eligibility rules, claim routing, and reconciliation logic stay welded to the same old rebate settlement habits.

This is the part the industry keeps trying to dress up as strategy. It is not strategy. It is plumbing. The pricing master, the formulary service, the claims switch, the rebate file, the audit trail, the transaction facilitator, the payment timing. That is where reform either becomes real or collapses into an expensive press release.

Most of the so called momentum in drug price reform is unfinished plumbing wearing a keynote. Call it what it is, then fix the stack.

If this handoff problem is sitting in your system, write hello@example.com. We build the software side of the mess.